Advertisement
Advertisement
April 27, 2014
Lombard Medical Commences IPO
April 24, 2014—Lombard Medical, Inc. (Irvine, CA) announced the pricing of the initial public offering of 5,000,000 ordinary shares at a price to the public of $11 per share. The offering was listed on the NASDAQ Global Market under the ticker symbol “EVAR” on April 25, 2014. In addition, Lombard Medical, Inc. has granted the underwriters a 30-day option to purchase up to an additional 750,000 ordinary shares. Lombard focuses on medical devices for endovascular repair of abdominal aortic aneurysms (AAAs). The company’s lead product is the Aorfix endovascular stent graft, which it describes as having been specifically designed to solve the problems that exist in treating complex tortuous anatomy that is often present in advanced AAA disease.
The company announced on March 11 that a registration statement relating to these securities had been filed with, and declared effective by, the US Securities and Exchange Commission. Lombard Medical, Inc. will become the parent company of Lombard Medical Technologies PLC (Oxfordshire, UK).
Advertisement
Advertisement
